

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

**The Future of the Pharmaceutical Industry**

*Integrating New Drug Discovery & Development Technology with Complex Biological Systems Research*

December 13-14, 2001

The Royal Sonesta Hotel, Cambridge, Massachusetts

**PROGRAM AGENDA**

**Thursday, December 13**

7:45a.m. - 8:45a.m.

***Registration and Continental Breakfast***

The Grand Ballroom, Royal Sonesta Hotel

8:45a.m. - 12:00p.m.

**Technological Innovation and Complex Biological Systems: An Overview**

Anthony J. Sinskey, Sc.D., Professor of Microbiology, Department of Biology, MIT and Chairman of the Scientific Advisory Board, Program on the Pharmaceutical Industry and;

Stan N. Finkelstein, M.D., Senior Research Scientist, and Co-Director, Program on the Pharmaceutical Industry, MIT Sloan School of Management

**Technology Of The Future: Innovations In Identifying, Selecting And Exploiting Therapeutic Targets**

Anthony J. Sinskey, Moderator

**Genome-Wide Prediction of Signaling Pathways**

Michael Yaffe, Ph.D., M.D., Assistant Professor of Biology, Department of Biology, MIT

**Protein Microarrays and Functional Genomics: Multiplexing Analysis Strategy for Target Selection**

Gavin MacBeath, Ph.D., CGR Research Fellow, Center for Genomics Research, Harvard University

**Image Informatics for Drug Discovery and Target Identification**

Peter K. Sorger, Ph.D., Associate Professor of Biology and Biological Engineering, Department of Biology, MIT

**Integrated Chemical and Biological Microsystems for Discovery and Process Development**

Klavs F. Jensen, Ph.D., Lamot du Pont Professor of Chemical Engineering and Professor of Materials Science and Engineering, Department of Chemical Engineering, MIT

12:30p.m.- 1:30p.m.

***Luncheon***

1:30p.m. - 5:00p.m.

**From Molecule To Disease State: Innovative Models For Drug Development**

Anthony J. Sinskey, Moderator

**New Working Disease State Models for Computer-Aided Trial Design**

Terrance F. Blaschke, M.D. Ph.D., Professor of Medicine and Molecular Pharmacology, Stanford University and Vice President, Collaborative Programs, Pharsight Corporation

**OVER**

## PROGRAM AGENDA/2

### Thursday, December 13

1:30p.m. - 5:00p.m.  
(continued)

#### **New Working Models for Clinical Trials of Complex, Therapeutically Difficult Diseases Advances in Molecular Oncology: New Pathways to Personalized Medicine**

##### **Advances in Molecular Oncology**

John D. Haley, Ph.D., Senior Director of New Technology Development, OSI Pharmaceuticals, Inc.

##### **Advances in Technology and the Treatment of Diabetes Mellitus**

Alan C. Moses, M.D., Associate Professor of Medicine, Harvard Medical School and Medical Director, Joslin Clinic Division, Joslin Diabetes Center, Beth-Israel Deaconess Hospital

##### **Advances in the Treatment of Infectious Diseases**

Robert H. Rubin, M.D., Osborne Professor of Health Sciences and Technology and Director, Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology; and Professor of Medicine and Associate Director for Infectious Disease, Brigham and Women's Hospital

5:00p.m. - 6:00p.m.

#### ***Reception***

### Friday, December 14

7:45a.m. - 8:30a.m.

#### ***Continental Breakfast***

8:30a.m. - 12:30p.m.

#### **Innovations In Outcomes Research**

Thomas J. Allen, Ph.D., Moderator, Howard Johnson Professor of Management, MIT Sloan School of Management and Co-Director, Program on the Pharmaceutical Industry

#### **Analyzing the Efficacy of Medical Practices for Depression: Using IT to Facilitate the Use of Retrospective Data Analysis**

Stan N. Finkelstein, M.D.

#### **Removing Selection Bias From Treatment Analysis Outcomes**

William H. Crown, Ph.D., Vice President, Outcomes Research & Econometrics, the MEDSTAT Group

#### **Caveats of Randomized Clinical Trials for Economic Analysis: Dealing With Tensions Over Drug Costs**

Suzanne Wait, Ph.D., Associate Director of Outcomes Research, Bristol-Myers Squibb

#### **FDA Perspectives on the Use of Non-Randomized Controlled Data in Evaluating Pharmaceuticals**

Robert T. O'Neill, Ph.D., Director, Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration

12:30p.m.

#### ***Adjournment***

12:30p.m. - 1:30p.m.

#### ***Luncheon***